Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 9/20 | 1.00 |
| ▸ | CNR2 | P34972 | 4/20 | 0.89 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.89 |
| ▸ | GPR55 | Q9Y2T6 | 2/20 | 0.89 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.89 |
| ▸ | MLNR | O43193 | 1/20 | 0.89 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.89 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.89 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.89 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.89 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.89 |
| ▸ | DRD1 | P21728 | 1/20 | 0.89 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.89 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.89 |
| ▸ | HRH2 | P25021 | 1/20 | 0.89 |
| ▸ | HTR2A | P28223 | 1/20 | 0.89 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.89 |
| ▸ | CCKAR | P32238 | 1/20 | 0.89 |
| ▸ | CCKBR | P32239 | 1/20 | 0.89 |
| ▸ | MC4R | P32245 | 1/20 | 0.89 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Rimonabant SCHEMBL29373177 | 0.94 | CNR1 (1.00) | CNR1CNR2CYP2C9GPR55ABCC4 | |
| Rimonabant SCHEMBL38637 | 0.94 | CNR1 (1.00) | CNR1CNR2CYP2C9GPR55ABCC4 | |
| SCHEMBL13349332 | 0.93 | CNR1 (0.88) | CNR1CNR2CYP2C9GPR55ABCC4 | |
| Rimonabant SCHEMBL29835931 | 0.93 | CNR1 (1.00) | CNR1CNR2CYP2C9GPR55ABCC4 | |
| Rimonabant SCHEMBL1186698 | 0.93 | CNR1 (1.00) | CNR1CNR2CYP2C9GPR55ABCC4 | |
| SCHEMBL12053639 | 0.93 | CNR1 (0.98) | CNR1CNR2CYP2C9GPR55ABCC4 | |
| Rimonabant SCHEMBL746112 | 0.92 | CNR1 (0.96) | CNR1CNR2CYP2C9GPR55ABCC4 | |
| SCHEMBL14397516 | 0.92 | CNR1 (0.92) | CNR1CNR2CYP2C9GPR55ABCC4 | |
| Rimonabant SCHEMBL8742390 | 0.91 | CNR1 (0.94) | CNR1CNR2CYP2C9GPR55ABCC4 | |
| SCHEMBL29386088 | 0.91 | CNR1 (1.00) | CNR1CNR2CYP2C9GPR55ABCC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9084730-B2 | Pharmaceutical composition comprising a solid dispersion with a polymer matrix containing a continuous polydextrose phase and a continuous phase of a polymer other than polydextrose | SANOFI (FR) | 2015-07-21 | — | — | US | claimed |
| EP-1791524-B1 | PHARMACEUTICAL COMPOSITION COMPRISING A SOLID DISPERSION WITH A POLYMER MATRIX CONTAINING A CONTINUOUS POLYDEXTROSE PHASE AND A CONTINUOUS PHASE OF A POLYMER OTHER THAN POLYDEXTROSE | SANOFI SA (FR) | 2014-11-19 | — | — | EP | claimed |
| US-20070243257-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A SOLID DISPERSION WITH A POLYMER MATRIX CONTAINING A CONTINUOUS POLYDEXTROSE PHASE AND A CONTINUOUS PHASE OF A POLYMER OTHER THAN POLYDEXTROSE | SANOFI-AVENTIS (FR) | 2007-10-18 | — | — | US | claimed |
| EP-1752149-A1 | CB1 Antagonists or inverse agonists as therapeutical agents for the treatment of inflammation involving gene expression | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2007-02-14 | — | — | EP | claimed |
| EP-1743637-A1 | Use of substituted pyrazole compounds and combinations thereof for the treatment of the metabolic syndrome | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2007-01-17 | — | — | EP | claimed |
| US-9084730-B2 | Pharmaceutical composition comprising a solid dispersion with a polymer matrix containing a continuous polydextrose phase and a continuous phase of a polymer other than polydextrose | SANOFI (FR) | 2015-07-21 | — | — | US | disclosed |
| EP-1791524-B1 | PHARMACEUTICAL COMPOSITION COMPRISING A SOLID DISPERSION WITH A POLYMER MATRIX CONTAINING A CONTINUOUS POLYDEXTROSE PHASE AND A CONTINUOUS PHASE OF A POLYMER OTHER THAN POLYDEXTROSE | SANOFI SA (FR) | 2014-11-19 | — | — | EP | disclosed |
| US-8410097-B2 | Heteropyrrole analogs acting on cannabinoid receptors | UNIVERSITY OF CONNECTICUT (US) | 2013-04-02 | — | — | US | disclosed |
| US-8410097-B2 | Heteropyrrole analogs acting on cannabinoid receptors | UNIVERSITY OF CONNECTICUT (US) | 2013-04-02 | — | — | US | disclosed |
| US-8410097-B2 | Heteropyrrole analogs acting on cannabinoid receptors | UNIVERSITY OF CONNECTICUT (US) | 2013-04-02 | — | — | US | disclosed |
| US-20120095047-A1 | Novel Heteropyrrole Analogs Acting on Cannabinoid Receptors | UNIVERSITY OF CONNECTICUT (US) | 2012-04-19 | — | — | US | disclosed |
| US-20120095047-A1 | Novel Heteropyrrole Analogs Acting on Cannabinoid Receptors | UNIVERSITY OF CONNECTICUT (US) | 2012-04-19 | — | — | US | disclosed |
| US-20040192667-A1 | Novel pyrazole analogs acting on cannabinoid receptors | UNIVERSITY OF CONNECTICUT | 2004-09-30 | — | — | US | disclosed |
| US-20040039024-A1 | Pyrazolecarboxylic acid derivatives, their preparation and pharmaceutical compositions containing them | SANOFI-AVENTIS (FR) | 2004-02-26 | — | — | US | disclosed |
| US-6645985-B2 | Pyrazolecarboxylic acid derivatives, their preparation and pharmaceutical compositions containing them, and method of treating | SANOFI (FR) | 2003-11-11 | — | — | US | disclosed |
| EP-1150961-B1 | PYRAZOLECARBOXYLIC ACID DERIVATIVES, THEIR PREPARATION, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | SANOFI SYNTHELABO (FR) | 2003-10-22 | — | — | EP | disclosed |
| US-20020188007-A1 | Pyrazolecarboxylic acid derivatives, their preparation and pharmaceutical compositions containing them | SANOFI (FR) | 2002-12-12 | — | — | US | disclosed |
| US-6432984-B1 | CANNABINOID RECEPTOR ANTAGONISTS; TREATMENT OF OBESITY, DRUG ADDICTION, ALCHOLISM, PSYCHOLOGICAL, AND EATING DISORDERS | SANOFI-SYNTHELABO (FR) | 2002-08-13 | — | — | US | disclosed |
| EP-1150961-A1 | PYRAZOLECARBOXYLIC ACID DERIVATIVES, THEIR PREPARATION, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | SANOFI-SYNTHELABO (FR) | 2001-11-07 | — | — | EP | disclosed |
| WO-2000046209-A1 | PYRAZOLECARBOXYLIC ACID DERIVATIVES, THEIR PREPARATION, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | SANOFI-SYNTHELABO (FR) | 2000-08-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040039024-A1 | Pyrazolecarboxylic acid derivatives, their preparation and pharmaceutical compositions containing them | CNR1, CNR2, P2RY1 | CNR1 1/4885CNR2 2/4885CYP2C9 283/4885 |
| US-20040192667-A1 | Novel pyrazole analogs acting on cannabinoid receptors | CNR1, CNR2, P2RY1 | CNR1 1/4885CNR2 2/4885CYP2C9 661/4885 |
| US-20120095047-A1 | Novel Heteropyrrole Analogs Acting on Cannabinoid Receptors | CNR2, CNR1, GPR18 | CNR1 2/4885CNR2 1/4885CYP2C9 1185/4885 |
| US-20020188007-A1 | Pyrazolecarboxylic acid derivatives, their preparation and pharmaceutical compositions containing them | CNR1, CNR2, P2RY1 | CNR1 1/4885CNR2 2/4885CYP2C9 283/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.